Delving into the Latest Updates on Thioraviroc with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

CCR5

Action

antagonists

Mechanism

CCR5 antagonists(C-C chemokine receptor type 5 antagonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases+ [3]

Active Indication

Multiple SclerosisHIV InfectionsAmyotrophic Lateral Sclerosis

Inactive Indication-

Originator Organization

Shanghai Institute of Materia Medica Chinese Academy of Sci

Active Organization

Shanghai Institute of Materia Medica Chinese Academy of Sci

Beijing Tiantan Hospital

Kunming Institute of Zoology

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Main purpose: ? To evaluate the safety and tolerability of multiple oral administration of Seravino tablets in HIV-infected patients who have not received anti-HIV treatment. Secondary purpose: ? To investigate the pharmacokinetic characteristics of Seravino tablets after multiple administration in HIV-infected patients who have not received anti-HIV treatment and obtain pharmacokinetic parameters.

Start Date20 Mar 2023

Sponsor / Collaborator

Kunming Institute of Zoology

[+1]

CTR20200417

/ Active, not recruitingPhase 1IIT

塞拉维诺片在中国健康受试者中单次给药安全性、耐受性及药代动力学临床研究

[Translation] A clinical study on the safety, tolerability and pharmacokinetics of single-dose seravino tablets in healthy Chinese subjects

评估塞拉维诺片单次给药对中国健康受试者的安全性、耐受性；考察塞拉维诺片单次给药在中国健康受试者体内的药代动力学特性，获取药代动力学参数；为后续临床试验推荐剂量和给药方式提供依据。

[Translation]

To evaluate the safety and tolerability of a single dose of seravino tablets in healthy Chinese subjects; to investigate the pharmacokinetic characteristics of a single dose of seravino tablets in healthy Chinese subjects and obtain pharmacokinetic parameters; to provide a basis for recommending dosage and administration methods in subsequent clinical trials.

Start Date20 Mar 2020

Sponsor / Collaborator

Kunming Institute of Zoology

[+1]

CTR20202329

/ Not yet recruitingPhase 1IIT

在中国健康受试者中评价塞拉维诺片单中心、随机、开放、三周期交叉的食物影响临床研究

[Translation] Evaluation of Seravino tablets in healthy Chinese subjects Single-center, randomized, open-label, three-period crossover clinical study on the effect of food

主要目的：评价食物对塞拉维诺片药代动力学及安全性的影响；次要目的：进行中国健康受试者口服塞拉维诺片后粪样药物浓度探索性研究。

[Translation]

Primary objective: To evaluate the effect of food on the pharmacokinetics and safety of Seravino tablets; Secondary objective: To conduct an exploratory study on fecal drug concentrations in healthy Chinese subjects after oral administration of Seravino tablets.

Start Date-

Sponsor / Collaborator

Kunming Institute of Zoology

[+1]

100 Clinical Results associated with Thioraviroc

Login to view more data

100 Translational Medicine associated with Thioraviroc

Login to view more data

100 Patents (Medical) associated with Thioraviroc

Login to view more data

100 Deals associated with Thioraviroc

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Sclerosis	Phase 2	China	Shanghai Institute of Materia Medica Chinese Academy of Sci	03 Jun 2026
Multiple Sclerosis	Phase 2	China	Beijing Tiantan Hospital	03 Jun 2026
HIV Infections	Phase 1	China	Shanghai Institute of Materia Medica Chinese Academy of Sci	20 Mar 2020
HIV Infections	Phase 1	China	Kunming Institute of Zoology	20 Mar 2020
Amyotrophic Lateral Sclerosis	IND Approval	China	Shanghai Institute of Materia Medica Chinese Academy of Sci	02 Feb 2026